RLS-1496 Phase 1 Results: Rubedo Reports Progress Against Skin Aging

Rubedo Life Sciences announced positive early outcomes from its first human clinical trial of RLS-1496, a potential first-in-class senotherapeutic designed to selectively target “zombie/aged” cells tied to skin aging and biological aging processes. The company completed Phase 1 with a short 4-week study in Europe focused on safety, tolerability, and early efficacy signals. In RLS-1496 testing, patients with eczema, psoriasis, and sun-damaged skin were treated at mid and high doses. Rubedo said the treatment was well-tolerated, with no serious side effects. It reported an overall reduction in zombie cells. In one month, 25% of eczema patients saw a significant decline in skin itching, psoriasis patients showed about a 20% average reduction in skin thickness, and sun-damaged skin patients had increased collagen gene and protein expression linked to skin firmness. Rubedo also plans a second U.S. study later in 2026. That trial will evaluate whether RLS-1496 can help treat precancerous skin spots (actinic keratosis). Together, the two trials are expected to involve roughly 70 human subjects, with more data anticipated by the end of 2026. For traders, this is biotech/clinical news with no direct link to crypto markets, but it reflects broader life-science progress where risk appetite can occasionally spill over to tech-linked narratives. RLS-1496 remains a watch item as larger trials progress, though the immediate market impact is likely limited.